View Older Stories View More Recent Stories

May 6, 2024 07:15AM SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
Apr 4, 2024 07:15AM SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
Mar 29, 2024 07:15AM SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Feb 23, 2024 08:00AM SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
Jan 24, 2024 04:21AM SAB Biotherapeutics (SABS) Regains Nasdaq Compliance
Jan 23, 2024 05:58PM SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nov 14, 2023 07:30AM SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
Nov 14, 2023 07:15AM SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
Oct 19, 2023 07:30AM SAB Biotherapeutics (SABS) Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142
Oct 19, 2023 07:30AM SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
May 19, 2023 08:30AM SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
Apr 26, 2023 08:30AM SAB Biotherapeutics (SABS) Reports Positive Results from Phase 3 Trial of SAB-185
Apr 26, 2023 08:30AM SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
Apr 18, 2023 08:32AM SAB Biotherapeutics (SABS) Granted FDA Breakthrough Therapy Designation for SAB-176
Apr 18, 2023 08:30AM SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
Apr 13, 2023 08:31AM SAB Biotherapeutics (SABS) Granted Fast Track Designation from FDA for SAB-176
Apr 13, 2023 08:30AM SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
Apr 4, 2023 08:07AM SAB Biotherapeutics (SABS) Announces Appointment of Erick Lucera, CFA to Board of Directors
Apr 4, 2023 08:00AM SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
Mar 31, 2023 05:00PM SAB Biotherapeutics Provides Company Update for Full Year 2022
Mar 23, 2023 04:13PM ICR Hosts SAB Biotherapeutics CEO Eddie Sullivan on the Welcome to the Arena Podcast
Jan 19, 2023 08:00AM SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
Jan 18, 2023 08:05AM SAB Biotherapeutics (SABS) Receives an Additional $8.2 Million in Closeout of DoD Contract
Jan 18, 2023 08:00AM SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
Jan 10, 2023 08:00AM SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
Jan 10, 2023 08:00AM SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
Jan 9, 2023 08:00AM SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
Jan 5, 2023 08:00AM SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
Dec 15, 2022 08:30AM SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
Dec 7, 2022 05:26PM SAB Biotherapeutics (SABS) Sells 7.3M Shares w/Warrants in Private Placement
Dec 7, 2022 05:16PM SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
Dec 7, 2022 05:16PM SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
Nov 21, 2022 08:15AM SAB Biotherapeutics (SABS) Initiates IND-Enabling GLP Toxicology Study for SAB-142
Nov 21, 2022 08:14AM SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
Nov 21, 2022 08:14AM SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
Nov 15, 2022 08:30AM SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
Nov 8, 2022 08:30AM SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
Nov 3, 2022 09:05AM SAB Biotherapeutics (SABS) Presents Overview of DiversitAb Platform and Data Showing Benefits
Nov 3, 2022 09:00AM SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotec
Oct 27, 2022 08:30AM SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
Oct 27, 2022 08:30AM SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
Sep 28, 2022 08:06AM SAB Biotherapeutics (SABS) Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective
Sep 28, 2022 08:00AM SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against
Sep 28, 2022 08:00AM SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against
Sep 23, 2022 08:32AM SAB Biotherapeutics (SABS) Reports New Data on SAB-176 Phase 2 Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants
Sep 23, 2022 08:30AM SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants
Sep 23, 2022 08:30AM SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants
Aug 10, 2022 08:15AM SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results
Aug 9, 2022 04:30PM SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
Aug 4, 2022 08:30AM SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update
View More Recent Stories View Older Stories